A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker

- Heinzelmann-Schwarz, Viola A., Nixdorf, Sheri, Valadan, Mehrnaz, Diczbalis, Monica, Olivier, Jake, Otton, Geoff, Fedier, André, Hacker, Neville F., Scurry, James P.

A Journey past the sun: group art psychotherapy for people with melanoma: An investigation using narrative and immunological and psychosocial measures

- Virago, Marie-Christina Elizabeth

A narrative review of the potential for self- tanning products to substitute for solaria use among people seeking a tanned appearance

- Paul, Christine L., Bryant, Jamie, Turon, Heidi, Brozek, Irena, Noble, Natasha, Zucca, Alison

A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner

- Sutton, Selina K., Carter, Daniel R., McArthur, Grant A., Cheung, Belamy B., Marshall, Glenn M., Kim, Patrick, Tan, Owen, Arndt, Greg M., Zhang, Xu Dong, Baell, Jonathan, Noll, Benjamin D., Wang, Shudong, Kumar, Naresh

A systematic review and meta-analysis of locoregional treatments for in-transit melanoma

- Read, Tavis, Lonne, Michael, Sparks, David S., David, Michael, Wagels, Michael, Schaider, Helmut, Soyer, H. Peter, Smithers, B. Mark

Actin crosslinking protein α-actinin-4 (ACTN4) regulates receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in melanoma

- Zhang, Yuanyuan

Activating kinase mutations in melanoma

- Vilain, Ricardo Enrique

Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells

- Zhu, Bi-ke, Wang, Ping, Zhang, Xu Dong, Jiang, Chen Chen, Chen, Li Hua, Avery-Kiejda, Kelly A., Watts, Ralph, Hersey, Peter

ACTN4 regulates the stability of RIPK1 in melanoma

- Zhang, Yuan Yuan, Tabataba, Hessam, Liu, Xiao Ying, Wang, Jia Yu, Yan, Xu Guang, Farrelly, Margaret, Jiang, Chen Chen, Guo, Su Tang, Liu, Tao, Kao, Hung-Ying, Thorne, Rick F., Zhang, Xu Dong, Jin, Lei

Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma

- Hersey, Peter, Zhang, Xu Dong

Adipocytes contribute to resistance of human melanoma cells to chemotherapy and targeted therapy

- Chi, M., Chen, J., Ye, Y., Tseng, Hsin-Yi, Lai, F., Tay, K. H., Jin, L., Guo, S. T., Jiang, C. C., Zhang, X. D.

Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

- Weber, Jeffrey S., Schadendorf, Dirk, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Del Vecchio, Michele, Brown, Michael P., Rutkowski, P, Haydon, A, Grob, J-J, Schachter, J, Queirolo, P, de la Cruz-Merino, L, van der Westhuizen, Andre, Menzies, AM, Re, S, Larkin, James, Bas, T, de Pril, V, Braverman, J, Tenney, DJ, Tang, H, Long, GV, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

- Hu, W., Jin, L., Jiang, C. C., Long, G. V., Scolyer, R. A., Wu, Q., Zhang, X. D., Mei, Y., Wu, M.

Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report

- McGuire, Helen M., Shklovskaya, Elena, Edwards, Jarem, Trevillian, Paul R., McCaughan, Geoffrey W., Bertolino, Patrick, McKenzie, Catriona, Gourlay, Ralph, Gallagher, Stuart J., Fazekas de St. Groth, Barbara, Hersey, Peter

Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma

- Hersey, Peter

Apoptosis of human melanoma cells induced by inhibition of B-RAFᵛ⁶⁰⁰ᴱ involves preferential splicing of bimS

- Jiang, C. C., Lai, F., Zhang, X. D., Tay, K. H., Croft, A., Rizos, H., Becker, T. M., Yang, F., Liu, H., Thorne, R. F., Hersey, P.

Association of pembrolizumab with tumor response and survival among patients with advanced melanoma

- Ribas, Antoni, Hamid, Omid, Gangadhar, Tara C., Hersey, Peter, Dronca, Roxana, Joseph, Richard W., Zarour, Hassane, Chmielowski, Bartosz, Lawrence, Donald P., Algazi, Alain, Rizvi, Naiyer A., Hoffner, Brianna, Daud, Adil, Mateus, Christine, Gergich, Kevin, Lindia, Jill A., Giannotti, Maxine, Li, Xiaoyun Nicole, Ebbinghaus, Scott, Kang, S. Peter, Robert, Caroline, Hodi, F. Stephen, Wolchok, Jedd D., Kefford, Richard, Joshua, Anthony M., Patnaik, Amita, Hwu, Wen-Jen, Weber, Jeffrey S.

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group

- Bedikian, Agop Y., Millward, Michael, Kirkwood, John M., Haluska, Frank G., Pehamberger, Hubert, Conry, Robert, Gore, Martin, Trefzer, Uwe, Pavlick, Anna C., DeConti, Ronald, Hersh, Evan M., Hersey, Peter

Biomarkers in melanoma

- Gogas, H., Eggermont, A. M. M., Hauschild, A., Hersey, P., Mohr, P., Schadendorf, D., Spatz, A., Dummer, R.

BRAF and NRAS mutational status are prognostically important in thick and locally advanced cutaneous melanoma

- Vilain, R., Braye, S. G., Ashman, L., Scott, R. J.